Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an announcement.
Xspray Pharma has appointed Blake Leitch as its new CEO, effective no later than June 1, 2026, bringing more than two decades of global commercial experience from roles at Biocon Biologics, Biogen and Bayer. He will focus on scaling the company’s commercial operations as it transitions into a fully fledged pharmaceutical business with multiple oncology candidates under regulatory review.
Current CEO and company founder Per Andersson will shift to the role of Chief Scientific Officer, dedicating his efforts to accelerating research, advancing the HyNap platform and expanding the pipeline of value-enhanced cancer drugs. The leadership reshuffle is designed to balance commercial and scientific strengths, positioning Xspray to capitalize on its late stage assets and technology as it seeks a stronger foothold in the oncology market.
The most recent analyst rating on (SE:XSPRAY) stock is a Hold with a SEK27.00 price target. To see the full list of analyst forecasts on Xspray Pharma AB stock, see the SE:XSPRAY Stock Forecast page.
More about Xspray Pharma AB
Xspray Pharma AB is a Swedish pharmaceutical company developing improved versions of marketed protein kinase inhibitors, the largest oncology market segment, using its patented HyNap technology platform. Its lead candidates include Dasynoc, an optimized dasatinib, and XS003-nilotinib, both under FDA review, alongside a growing portfolio targeting cancer treatments such as axitinib and cabozantinib.
Average Trading Volume: 48,978
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.09B
For detailed information about XSPRAY stock, go to TipRanks’ Stock Analysis page.